Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 101–200 of 1,000
Coltro, G., Mangaonkar, A. A., Lasho, T. L., Finke, C. M., Pophali, P. A., Carr, R. M., Gangat, N., Binder, M., Pardanani, A. D., Fernández-Zapico, M. E., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0690-7 · Cited by 112
Mintz, M. A., Felce, J. H., Chou, M. Y., Mayya, V., Xu, Y., Shui, J.-W., An, J., Li, Z., Marson, A., Okada, T., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.022 · Cited by 110
Circulating Tumor DNA in Lymphoma: Principles and Future Directions
Roschewski, M. J., Rossi, D., Kurtz, D. M., Alizadeh, A. A., & Wilson, W. H. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0029 · Cited by 110
Self-citationWhole-genome landscape of adult T-cell leukemia/lymphoma
Kogure, Y., Kameda, T., Koya, J., Yoshimitsu, M., Nosaka, K., Yasunaga, J., Imaizumi, Y., Watanabe, M., Saito, Y., Ito, Y., et al. (2021) · Blood · doi:10.1182/blood.2021013568 · Cited by 110
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
George, B., Chowdhury, S. M., Hart, A., Sircar, A., Singh, S. K., Nath, U. K., Mamgain, M., Singhal, N. K., Sehgal, L., & Jain, N. K. (2020) · Cancers · doi:10.3390/cancers12051328 · Cited by 109
Lauer, E. M., Mutter, J., & Scherer, F. (2022) · Leukemia · doi:10.1038/s41375-022-01618-w · Cited by 109
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups
Egan, C., Nicolae, A., Lack, J., Chung, H., Skarshaug, S., Pham, T., Navarro, W., Abdullaev, Z., Aguilera, N. S. I., Xi, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.230375 · Cited by 108
Self-citationLio, C. J., Shukla, V., Samaniego‐Castruita, D., González‐Avalos, E., Chakraborty, A., Yue, X., Schatz, D. G., Ay, F., & Rao, A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau7523 · Cited by 108
Rivas‐Delgado, A., Nadeu, F., Enjuanes, A., Casanueva-Eliceiry, S., Mozas, P., Magnano, L., de Anta, N. C., Rovira, J., Dlouhy, I., Martín, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2558 · Cited by 105
Self-citationNakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104
Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma
Ennishi, D., Hsi, E. D., Steidl, C., & Scott, D. W. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0174 · Cited by 104
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Bonfiglio, F., Bruscaggin, A., Guidetti, F., di Bergamo, L. T., Faderl, M., Spina, V., Condoluci, A., Bonomini, L., Forestieri, G., Koch, R., et al. (2021) · Blood · doi:10.1182/blood.2021012386 · Cited by 103
Self-citationInsights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
Hunter, Z. R., Xu, L., Tsakmaklis, N., Demos, M. G., Kofides, A., Jiménez, C., Chan, G., Chen, J. G., Liu, X., Munshi, M. N., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022962 · Cited by 101
Self-citationYTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
Chen, Z., Zeng, C., Yang, L., Che, Y., Chen, M., Sau, L., Wang, B., Zhou, K., Chen, Y., Qing, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.007 · Cited by 101
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Parry, E. M., Leshchiner, I., Guièze, R., Johnson, C., Tausch, E., Parikh, S. A., Lemvigh, C. K., Broséus, J., Hergalant, S., Messer, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02113-6 · Cited by 99
Self-citationZhou, X., Chen, N., Xu, H., Zhou, X., Wang, J., Fang, X., Zhang, Y., Li, Y., Yang, J., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00906-1 · Cited by 98
Self-citationShukla, V., Samaniego‐Castruita, D., Dong, Z., González‐Avalos, E., Yan, Q., Sarma, K., & Rao, A. (2021) · Nature Immunology · doi:10.1038/s41590-021-01087-w · Cited by 98
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
Thomas, N., Dreval, K., Gerhard, D. S., Hilton, L. K., Abramson, J. S., Ambinder, R. F., Barta, S. K., Bartlett, N. L., Bethony, J. M., Bhatia, K. G., et al. (2022) · Blood · doi:10.1182/blood.2022016534 · Cited by 98
Self-citationTkachenko, A. S., Kupcová, K., & Havránek, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010010 · Cited by 98
S-Geranylgeranyl-l-glutathione is a ligand for human B cell-confinement receptor P2RY8
Lu, E., Wolfreys, F. D., Muppidi, J. R., Xu, Y., & Cyster, J. G. (2019) · Nature · doi:10.1038/s41586-019-1003-z · Cited by 97
Isshiki, Y., Chen, X., Teater, M. R., Karagiannidis, I., Nam, H. S., Cai, W., Meydan, C., Xia, M., Shen, H., Gutierrez, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.006 · Cited by 97
de Groen, R. A. L., Schrader, A. M. R., Kersten, M. J., Pals, S. T., & Vermaat, J. S. P. (2019) · Haematologica · doi:10.3324/haematol.2019.227272 · Cited by 97
Pascual, M., Mena-Varas, M., Robles, E. F., Garcia-Barchino, M.-J., Panizo, C., Hervas-Stubbs, S., Alignani, D., Sagardoy, A., Martinez-Ferrandis, J. I., Bunting, K. L., et al. (2019) · Blood · doi:10.1182/blood.2018889931 · Cited by 96
Giroud, J., Bouriez, I., Paulus, H., Pourtier, A., Debacq-Chainiaux, F., & Pluquet, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310788 · Cited by 73
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
Melani, C. J., Lakhotia, R., Pittaluga, S., Phelan, J. D., Huang, D. W., Wright, G. W., Simard, J. L., Muppidi, J. R., Thomas, C. J., Ceribelli, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401532 · Cited by 97
Self-citationGong, C., Krupka, J. A., Gao, J., Grigoropoulos, N. F., Giotopoulos, G., Asby, R., Screen, M., Usheva, Z., Cucco, F., Barrans, S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2021.07.041 · Cited by 95
Self-citationPrecision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Lue, J. K., Prabhu, S. A., Liu, Y., Gonzalez, Y., Verma, A., Mundi, P. S., Abshiru, N. A., Camarillo, J. M., Mehta, S., Chen, E. I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3989 · Cited by 95
Falini, B., Martino, G., & Lazzi, S. (2022) · Leukemia · doi:10.1038/s41375-022-01764-1 · Cited by 94
Vermaat, J. S. P., Somers, S. F., de Wreede, L. C., Kraan, W., de Groen, R. A. L., Schrader, A. M. R., Kerver, E. D., Scheepstra, C. G., Berenschot, H. W., Deenik, W., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214122 · Cited by 93
Lugtenburg, P. J., Brown, P. D. N., van der Holt, B., d’Amore, F., Koene, H. R., de Jongh, E., Fijnheer, R., van Esser, J. W. J., Böhmer, L. H., Pruijt, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03418 · Cited by 94
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
Klintman, J., Appleby, N., Stamatopoulos, B., Ridout, K., Eyre, T. A., Robbe, P., Pascua, L. L., Knight, S. J. L., Dreau, H. M.-P., Cabes, M., et al. (2020) · Blood · doi:10.1182/blood.2020005650 · Cited by 93
Self-citationShimada, K., Yoshida, K., Suzuki, Y., Iriyama, C., Inoue, Y., Sanada, M., Kataoka, K., Yuge, M., Takagi, Y., Kusumoto, S., et al. (2020) · Blood · doi:10.1182/blood.2020007245 · Cited by 93
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Tekle, G. E., Bernasocchi, T., Unni, A. M., Bertoni, F., Rossi, D., Rubin, M. A., & Theurillat, J.-P. P. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.009 · Cited by 93
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma
Xu, W., Berning, P., & Lenz, G. (2021) · Blood · doi:10.1182/blood.2020006784 · Cited by 93
Self-citationEfremov, D. G., Turkalj, S., & Laurenti, L. (2020) · Cancers · doi:10.3390/cancers12061396 · Cited by 92
Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease
Bedsaul-Fryer, J. R., Carter, N. M., Deibel, K. E., Hutcherson, S. M., Jones, T. A., Wang, Z., Yang, C., Yang, Y., & Pomerantz, J. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02105 · Cited by 92
Self-citationCancer Progress and Priorities: Childhood Cancer
Lupo, P. J., & Spector, L. G. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0941 · Cited by 91
Molecular pathogenesis of germinal center‐derived B cell lymphomas
Pasqualucci, L. (2019) · Immunological Reviews · doi:10.1111/imr.12745 · Cited by 91
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
Parvin, S., Ramírez-Labrada, A., Aumann, S., Lu, X., Weich, N., Santiago, G. E., Cortizas, E. M., Sharabi, E., Zhang, Y., Sánchez-García, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.007 · Cited by 91
Genetic modification of primary human B cells to model high-grade lymphoma
Caeser, R., Re, M. D., Krupka, J. A., Gao, J., Lara‐Chica, M., Dias, J. M. L., Cooke, S. L., Fenner, R. E., Usheva, Z., Runge, H. F. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12494-x · Cited by 90
Self-citationTargeting Bruton’s Tyrosine Kinase in CLL
Ahn, I. E., & Brown, J. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687458 · Cited by 78
Sobolewska, B., Chee, S.-P., Zaguia, F., Goldstein, D. A., Smith, J. R., Fend, F., Mochizuki, M., & Zierhut, M. (2021) · Cancers · doi:10.3390/cancers13163921 · Cited by 90
A modular transcriptome map of mature B cell lymphomas
Loeffler‐Wirth, H., Kreuz, M., Hopp, L., Arakelyan, A., Haake, A., Cogliatti, S., Feller, A. C., Hansmann, M., Lenze, D., Mӧller, P., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0637-7 · Cited by 91
Self-citationMolecular profiling of EBV associated diffuse large B-cell lymphoma
Frontzek, F., Staiger, A. M., Stelmach, R., Grau, M., Zapukhlyak, M., Kurz, K. S., Horn, H., Erdmann, T., Fend, F., Richter, J., et al. (2023) · Leukemia · doi:10.1038/s41375-022-01804-w · Cited by 89
Self-citationTakahara, T., Nakamura, S., Tsuzuki, T., & Satou, A. (2023) · Cancers · doi:10.3390/cancers15030835 · Cited by 89
Roider, T., Baertsch, M., Fitzgerald, D., Vöhringer, H. S., Brinkmann, B. J., Czernilofsky, F., Knoll, M., Cid, L. L., Mathioudaki, A., Faßbender, B., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01358-2 · Cited by 90
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma
Ramis-Zaldivar, J. E., González‐Farré, B., Nicolae, A., Pack, S., Clot, G., Nadeu, F., Mottok, A., Horn, H., Song, J. Y., Fu, K., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.271957 · Cited by 88
Self-citationVisco, C., Tanasi, I., Quaglia, F. M., Ferrarini, I., Fraenza, C., & Krampera, M. (2020) · Cancers · doi:10.3390/cancers12102913 · Cited by 87
Davies, A. J., Barrans, S., Stanton, L., Caddy, J., Wilding, S. A., Saunders, G. N., Mamot, C., Novak, U., McMillan, A., Fields, P. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00033 · Cited by 87
Andrades, Á., Peinado, P., Álvarez-Pérez, J. C., Sanjuán‐Hidalgo, J., García, D. J., Arenas, A. M., Matia‐González, A. M., & Medina, P. P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01736-8 · Cited by 86
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma
Ma, M. C. J., Tadros, S., Bouska, A. C., Heavican, T. B., Yang, H., Deng, Q., Moore, D. Y., Akhter, A., Hartert, K. T., Jain, N. K., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.274258 · Cited by 85
Relocalizing transcriptional kinases to activate apoptosis
Sarott, R. C., Gourisankar, S. P., Karim, B. A., Nettles, S. A., Yang, H., Dwyer, B. G., Simanauskaite, J., Tse, J., Abuzaid, H. Z., Krokhotin, A., et al. (2024) · Science · doi:10.1126/science.adl5361 · Cited by 86
Shen, R., Xu, P., Wang, N., Yi, H., Dong, L., Fu, D., Huang, J., Huang, H., Janin, A., Cheng, S., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.221 · Cited by 84
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
Vodička, P., Klener, P., & Trněný, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s326632 · Cited by 84
Berhan, A., Almaw, A., Damtie, S., & Solomon, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-01958-w · Cited by 84
Ceriani, L., Gritti, G., Cascione, L., Pirosa, M. C., Polino, A., Ruberto, T., Stathis, A., Bruno, A., Moccia, A. A., Giovanella, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001201 · Cited by 87
The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies
Arruga, F., Vaisitti, T., & Deaglio, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00550 · Cited by 83
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
Pararajalingam, P., Coyle, K. M., Arthur, S. E., Thomas, N., Alcaide, M., Meissner, B., Boyle, M., Qureshi, Q., Grande, B. M., Rushton, C. K., et al. (2020) · Blood · doi:10.1182/blood.2019002385 · Cited by 83
Self-citationEnnishi, D., Healy, S., Bashashati, A., Saberi, S., Hother, C. E., Mottok, A., Chan, F. C., Chong, L. C., Abraham, L., Kridel, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0757-z · Cited by 82
Self-citationDrug Resistance in Non-Hodgkin Lymphomas
Klener, P., & Klánová, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062081 · Cited by 82
Prevention and management of secondary central nervous system lymphoma
Bobillo, S., Khwaja, J., Ferreri, A. J. M., & Cwynarski, K. (2022) · Haematologica · doi:10.3324/haematol.2022.281457 · Cited by 81
Genetic and epigenetic insights into cutaneous T-cell lymphoma
Tensen, C. P., Quint, K. D., & Vermeer, M. H. (2021) · Blood · doi:10.1182/blood.2019004256 · Cited by 80
Advances in biology, diagnosis and treatment of DLBCL
Shi, Y., Xu, Y. X., Shen, H., Jin, J., Tong, H., & Xie, W. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05880-z · Cited by 81
Deep Learning for the Classification of Non-Hodgkin Lymphoma on Histopathological Images
Steinbuss, G., Kriegsmann, M., Zgorzelski, C., Brobeil, A., Goeppert, B., Dietrich, S., Mechtersheimer, G., & Kriegsmann, K. (2021) · Cancers · doi:10.3390/cancers13102419 · Cited by 79
Primary mediastinal large B-cell lymphoma
Savage, K. J. J. (2021) · Blood · doi:10.1182/blood.2020008376 · Cited by 79
RNA-binding proteins in hematopoiesis and hematological malignancy
Hodson, D. J., Screen, M., & Turner, M. (2019) · Blood · doi:10.1182/blood-2018-10-839985 · Cited by 78
Self-citationErnst, M., Oeser, A., Besiroglu, B., Caro-Valenzuela, J., Aziz, M. A. A. E., Monsef, I., Borchmann, P., Estcourt, L. J., Skoetz, N., & Goldkuhle, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013365.pub2 · Cited by 79
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy
Egan, C., Lack, J., Skarshaug, S., Pham, T., Abdullaev, Z., Xi, L., Pack, S., Pittaluga, S., Jaffe, E. S., & Raffeld, M. A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00673-x · Cited by 78
Self-citationLiquid biopsy in lymphoma: Molecular methods and clinical applications
Cirillo, M., Craig, A. F. M., Borchmann, S., & Kurtz, D. M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102106 · Cited by 76
The molecular hallmarks of primary and secondary vitreoretinal lymphoma
Bonzheim, I., Sander, P., Salmerón‐Villalobos, J., Süßkind, D., Szurman, P., Gekeler, F., Spitzer, M. S., Steinhilber, J., Kohler, E., Büssgen, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004212 · Cited by 76
Self-citationHashwah, H., Bertram, K., Stirm, K., Stelling, A., Wu, C. T., Kasser, S., Manz, M. G., Theocharides, A. P. A., Tzankov, A., & Mueller, A. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910576 · Cited by 76
Huse, K., Bai, B., Hilden, V. I., Bollum, L. K., Våtsveen, T. K., Munthe, L. A., Smeland, E. B., Irish, J. M., Wälchli, S., & Myklebust, J. H. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200144 · Cited by 75
TRAF3 as a Multifaceted Regulator of B Lymphocyte Survival and Activation
Bishop, G. A., Stunz, L. L., & Hostager, B. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02161 · Cited by 77
Lenz, G., Hawkes, E. A., Verhoef, G. E. G., Haïoun, C., Lim, S. T., Heo, D. S., Ardeshna, K. M., Chong, G., Haaber, J., Shi, W., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0743-y · Cited by 75
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Wang, Y., Farooq, U., Link, B. K., Larson, M. C., King, R. L., Maurer, M. J., Allmer, C., Hefazi, M., Thompson, C. A., Micallef, I. N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00014 · Cited by 74
Smith, C. I. E., & Burger, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689472 · Cited by 74
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood · doi:10.1182/blood.2019002395 · Cited by 72
“General physical health deterioration 14 (14) 6 (6) 2 (8) 1 (4) 7 (18) 3 (8) 3 (17) 2 (11)”
InfluentialOllila, T. A., Kurt, H., Waroich, J., Vatkevich, J., Sturtevant, A., Patel, N. R., Dubielecka, P. M., Treaba, D. O., & Olszewski, A. J. (2020) · Blood · doi:10.1182/blood.2020007236 · Cited by 72
Kurz, K. S., Ott, M., Kalmbach, S., Steinlein, S., Kalla, C., Horn, H., Ott, G., & Staiger, A. M. (2023) · Cancers · doi:10.3390/cancers15082285 · Cited by 71
Self-citationRunge, H. F. P., Lacy, S., Barrans, S., Beer, P. A., Painter, D., Smith, A. G., Roman, E., Burton, C., Crouch, S., Tooze, R. M., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17132 · Cited by 71
Self-citationR-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
Wang, L., & Li, L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001294 · Cited by 71
CAR T-Cell Therapy for Large B-Cell Lymphoma — Who, When, and How?
Roschewski, M., Longo, D. L., & Wilson, W. H. (2022) · New England Journal of Medicine · doi:10.1056/nejme2118899 · Cited by 70
Self-citationBRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis
Schmitt, A. M., Grimm, M., Kreienkamp, N., Junge, H., Labisch, J., Schuhknecht, L., Schönfeld, C., Görsch, E., Tibello, A., Menck, K., et al. (2023) · Blood · doi:10.1182/blood.2022019274 · Cited by 70
Hübschmann, D., Kleinheinz, K., Wagener, R., Bernhart, S. H., López, C., Toprak, U. H., Sungalee, S., Ishaque, N., Kretzmer, H., Kreuz, M., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01251-z · Cited by 69
Self-citationOvercoming Acquired Epigenetic Resistance to BTK Inhibitors
Shaffer, A. L., Phelan, J. D., Wang, J. Q., Huang, D., Wright, G. W., Kasbekar, M., Choi, J., Young, R. M., Webster, D. E., Yang, Y., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0063 · Cited by 61
Self-citationTumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Apollonio, B., Spada, F., Petrov, N., Cozzetto, D., Papazoglou, D., Jarvis, P., Kannambath, S., Terranova-Barberio, M., Amini, R., Enblad, G., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166070 · Cited by 69
Krogh, N., Asmar, F., Côme, C., Munch‐Petersen, H. F., Grønbæk, K., & Nielsen, H. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa035 · Cited by 69
Autio, M. I., Leivonen, S., Brück, O. E., Karjalainen‐Lindsberg, M., Pellinen, T. S., & Leppä, S. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3140 · Cited by 68
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
Nastoupil, L. J., & Bartlett, N. L. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01848 · Cited by 68
Self-citationCerchietti, L. C. A. (2024) · Blood · doi:10.1182/blood.2023021002 · Cited by 68
Chapuy, B., Wood, T., Stewart, C., Dunford, A. J., Wienand, K., Khan, S. J., Serin, N., Wang, M., Calabretta, E., Shimono, J., et al. (2024) · Blood · doi:10.1182/blood.2024025652 · Cited by 68
The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma
Avery, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00023 · Cited by 67
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
Kostakoglu, L., Martelli, M., Sehn, L. H., Belada, D., Carella, A.-M., Chua, N. S., González-Barca, E. M., Hong, X., Pinto, A., Shi, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002690 · Cited by 67
The regulatory role of PDE4B in the progression of inflammatory function study
Su, Y., Ding, J., Yang, F., He, C., Xu, Y., Zhu, X., Zhou, H., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982130 · Cited by 66
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma
Hilton, L. K., Ngu, H. S., Collinge, B. J., Dreval, K., Ben‐Neriah, S., Rushton, C. K., Wong, J., Cruz, M., Roth, A. J. L., Boyle, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00570 · Cited by 66
Thiéblemont, C., da Silva, M. G., Leppä, S., Lenz, G., Cottereau, A., Fox, C. P., López‐Guillermo, A., Illidge, T., Jurczak, W. J., Eich, H. T., et al. (2025) · HemaSphere · doi:10.1002/hem3.70207 · Cited by 66
Self-citationWestin, J. R., Davis, R. E., Feng, L., Hagemeister, F. B., Steiner, R. E., Lee, H. J., Fayad, L., Nastoupil, L. J., Ahmed, S., Rodriguez, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00597 · Cited by 65
Novel precision medicine approaches and treatment strategies in hematological malignancies
Rosenquist, R., Bernard, E., Erkers, T., Scott, D. W., Itzykson, R., Rousselot, P. H., Soulier, J., Hutchings, M., Östling, P., Cavelier, L. B., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13697 · Cited by 64
Liu, M., Bertolazzi, G., Sridhar, S., Lee, R. X., Jaynes, P. W., Mulder, K., Syn, N. L. X., Hoppe, M. M., Shuangyi, F., Peng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46220-z · Cited by 65
Roschewski, M. J., Phelan, J. D., & Wilson, W. H. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000450 · Cited by 66
Self-citation
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.